Cancer stage progression is likely to be correlated with the expression of HSF1, which indicates that HSF1 may be a useful biomarker for HCC prognosis and the development of novel therapeutic strategies for its treatment. The gene discussed is HSF1; the disease is hepatocellular carcinoma.